Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences.
about
Promising new treatments for psoriasisPsoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case seriesAnti-TNFα therapy in the management of psoriasis: experience of a state referral centerXP-828L (Dermylex), a new whey protein extract with potential benefit for mild to moderate psoriasis.Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study.IL-22/STAT3-Induced Increases in SLURP1 Expression within Psoriatic Lesions Exerts Antimicrobial Effects against Staphylococcus aureus.Therapeutic potential of selectin antagonists in psoriasis.Clinical review of 202 patients with vulval lichen sclerosus: A possible association with psoriasis.What is a role of haeme oxygenase-1 in psoriasis? Current concepts of pathogenesis.Psoriasis and obesity: literature review and recommendations for management.A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency.The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions.Analysis of granulysin-mediated cytotoxicity in peripheral blood of patients with psoriatic arthritis.Reduced CD26bright expression of peripheral blood CD8+ T-cell subsets in psoriatic patients.The role of cytokines in the pathomechanism of cutaneous disordersImmunomodulatory effects of a set of amygdalin analogues on human keratinocyte cells.Ultrastructural findings and tumor necrosis factor-alpha and intercellular adhesion molecule-1 expression in psoriasis patients before and after oral cyclosporin A therapy.Atorvastatin for the treatment of plaque-type psoriasis.The safety and efficacy of high-dose alefacept compared with a loading dose of alefacept in patients with chronic plaque psoriasis.
P2860
Q24598008-92E09989-FA5B-43BD-9B00-A62F56123C54Q24813225-20686683-A958-4FD5-8968-67DE34501E7DQ33752359-D34BC88B-AA38-47E4-AD6C-B7BBED17DBEFQ34585886-3E5E1BBD-E667-4085-A4EA-AE75C3C39B2BQ34740267-9836D66F-FF47-4679-9D91-A5877AB9F47DQ35810626-9BE4840B-A5A2-49D7-830C-D078144E4A85Q36543080-10BFB752-B3F2-41C8-AEBB-E9A10D7D779EQ36707588-E34FC4CE-DC16-40AE-A389-6D3E2C1BC170Q36780173-A1371EF5-A9F9-4DA8-9A5D-7ADB1527569AQ37777037-DF805FC4-613B-497A-A3E0-DC31FEAFF72FQ37898704-58A728DE-0885-4216-9C84-B5AED973C901Q38235809-4CC6C759-C9BD-49F5-A102-D4B517B21320Q39492477-56C15873-1960-490D-875A-253E296B1E14Q40117550-754EA678-DAC0-4E6A-A156-BBC928E6CDD3Q42167700-10A7485C-A699-44F4-9CF8-51CCEC94152AQ46758971-132A7871-21A4-43E8-AF68-14EDEFD382EDQ46975812-D2C9E57D-8633-4272-88C3-B64166BDAA9EQ50998182-C5C1F299-2C78-4689-A898-D17A2E3C41E4Q53430510-E454BBD3-2421-45C7-935A-88FA29CE0C68
P2860
Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Psoriasis: immunopathogenesis ...... c therapies; U.S. experiences.
@ast
Psoriasis: immunopathogenesis ...... c therapies; U.S. experiences.
@en
type
label
Psoriasis: immunopathogenesis ...... c therapies; U.S. experiences.
@ast
Psoriasis: immunopathogenesis ...... c therapies; U.S. experiences.
@en
prefLabel
Psoriasis: immunopathogenesis ...... c therapies; U.S. experiences.
@ast
Psoriasis: immunopathogenesis ...... c therapies; U.S. experiences.
@en
P2093
P2860
P1476
Psoriasis: immunopathogenesis ...... c therapies; U.S. experiences.
@en
P2093
P2860
P356
10.1111/J.1365-2133.2004.06009.X
P407
P577
2004-07-01T00:00:00Z